Ionis Pharmaceuticals’ Hold Rating Amid Promising HAE Trial Outcomes and Market Considerations
Analyst Michael Ulz of Morgan Stanley maintained a Hold rating on Ionis Pharmaceuticals (IONS – Research Report), with a price target of ...
Business Insider5d
Ionis Pharmaceuticals Hold Rating: Balancing Promising Data and Market Challenges
It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment ...
Mena FN4d
Familial Chylomicronemia Syndrome Market And Epidemiology 2034: Treatment FDA Approvals, Forecast By Delveinsight
Key Familial Chylomicronemia Syndrome Companies: Arrowhead Pharma, Visirna Therapeutics HK Limited, Ionis Pharmac, Novartis, Akcea Therapeutics, and others Key Familial Chylomicronemia Syndrome ...
Benzinga.com5d
Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug ...
Seeking Alpha2d
PTCT PTC Therapeutics, Inc.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally.
Forbes5d
Ionis Pharmaceuticals
It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment ...
ascopubs.org15d
Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia
Safety and Efficacy of CT041 in Patients With Refractory Metastatic Pancreatic Cancer: A Pooled Analysis of Two Early-Phase Trials Patients with Waldenström macroglobulinemia (WM) have disparate ...
Mena FN9d
Familial Chylomicronemia Syndrome Treatment Market Size, Share | Research 2024-32
(MENAFN- Meridian Market Consultants) The Reports and Insights, a leading market research company, has recently releases report titled “Familial Chylomicronemia Syndrome (FCS) treatment Market: Global ...
Morningstar1d
Ionis Pharmaceuticals Inc IONS
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
ascopubs.org14d
Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia
Safety and Efficacy of CT041 in Patients With Refractory Metastatic Pancreatic Cancer: A Pooled Analysis of Two Early-Phase Trials Patients with Waldenström macroglobulinemia (WM) have disparate ...
Joplin Globe16d
AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)
AstraZeneca and Alexion, AstraZeneca Rare Disease, will showcase 14 studies, including real-world evidence (RWE), from their portfolio and pipeline of investigational amyloidosis therapies at the ...
Yahoo Finance5d
Ionis Pharmaceuticals, Inc. (IONS)
After hours: June 5 at 4:01 PM EDT Loading Chart for IONS ...